2025 Q3 -tulosraportti
70 päivää sitten46 min
Tarjoustasot
Oslo Børs
Määrä
Osto
436
Myynti
Määrä
388
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 60 | - | - | ||
| 20 | - | - | ||
| 600 | - | - | ||
| 533 | - | - |
Ylin
74,8VWAP
Alin
73,1VaihtoMäärä
2,8 37 832
VWAP
Ylin
74,8Alin
73,1VaihtoMäärä
2,8 37 832
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 19.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·21 t sittenIt was quiet on the screen, the numbers were flat, red arrows whispered of a heavy night. But beneath the surface, in another land, a hope lay waiting – a yes from China's hand. Analyst's gaze and coffee cup, rumors spread before the sun comes up. Something is on its way, something is near, Cevira is knocking on a door there. And now Photocure rebounds on the stock exchange, like a wave finally finding its course. Expectations lift every single krone, China watches – and the market awakens to a tune. Yes, now Photocure rebounds on the stock exchange, faith meets numbers, and hope gets a pulse. Years of work, studies and faith, in lab and meetings, step by step in peace. A market so large, a light so clear, an approval can change everything, soon. The graphs tremble, the volume laughs, some buy early, others watch. It's not just about profit, but about future, patients, and a new beginning at last. And now Photocure rebounds on the stock exchange, after headwinds finally comes a course. Cevira in sight, China in play, the market answers: we believe, we will. Yes, now Photocure rebounds on the stock exchange, a small company with a global pulse. It's not just numbers going up and down, but stories of breakthroughs, hope and peace. When science meets patient time, even a stock can get new life. So now Photocure rebounds on the stock exchange, expectation becomes power, and power gets a course. If the approval comes – who knows when, but the market sings: we believe in this year. Yes, now Photocure rebounds on the stock exchange, and the future feels a little less dark.
·1 päivä sittenFrom user Aribijo on TI: From China forum: “The 1702 comprehensive review ended on December 26. The general administrative approval process takes 3-5 working days. The last step of drug approval is the administrative process, but it involves cross-departmental handover, and occasionally there will be a few days of delay. These two weeks after New Year’s Day are very critical time windows. There is a possibility of a drug registration approval at any time.”
·1 päivä sittenI have asked ChatGPT about the current status of approval with China's National Medical Products Administration (NMPA). Here is the answer: From Asieris' half-year report (August 2025): Asieris' CEO Dr. Kevin Pan stated: "A remarkable achievement is the steady progress in the regulatory review for APL-1702, our breakthrough therapy for precancerous lesions of the cervix, which is now entering the final stages before launch in China and is ready to benefit patients soon" The report further states that APL-1702 is "in the final stages before the China launch" and that "the regulatory review is progressing smoothly, with NMPA having initiated a second round of technical evaluation" Key signals Positive tone: The phrasing "steady progress" and "final stages" is a good sign. If there were major problems, such positive phrasing would hardly be used. Approval probability: APL-1702 is described as "ready to become the world's first non-invasive therapy for HSIL, supported by robust clinical evidence and validated in an international Phase III study" USA plans: Asieris has also entered into an agreement with FDA on the design of a new Phase III study to support potential USA approval of APL-1702, and the company is seeking foreign partners to prepare USA IND submission Based on this information from August 2025, it looks promising. The wording suggests that they expect approval relatively soon, and that there are no significant problems in the process. The fact that they are also planning for the USA market indicates confidence in the product.- ·1 päivä sittenTick tock tick tock. A decision on Cevira coming to market could be very close.·1 päivä sittenExtremely exciting days in PHO currently, the approval can literally come any day.
- ·2 päivää sittenIt didn't last long...... 💩💩
·1 päivä sitten5,5 mill. has been traded. That is quite a lot. The normal has been somewhere between 1,5-2. so this is a good sign.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
70 päivää sitten46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 t sittenIt was quiet on the screen, the numbers were flat, red arrows whispered of a heavy night. But beneath the surface, in another land, a hope lay waiting – a yes from China's hand. Analyst's gaze and coffee cup, rumors spread before the sun comes up. Something is on its way, something is near, Cevira is knocking on a door there. And now Photocure rebounds on the stock exchange, like a wave finally finding its course. Expectations lift every single krone, China watches – and the market awakens to a tune. Yes, now Photocure rebounds on the stock exchange, faith meets numbers, and hope gets a pulse. Years of work, studies and faith, in lab and meetings, step by step in peace. A market so large, a light so clear, an approval can change everything, soon. The graphs tremble, the volume laughs, some buy early, others watch. It's not just about profit, but about future, patients, and a new beginning at last. And now Photocure rebounds on the stock exchange, after headwinds finally comes a course. Cevira in sight, China in play, the market answers: we believe, we will. Yes, now Photocure rebounds on the stock exchange, a small company with a global pulse. It's not just numbers going up and down, but stories of breakthroughs, hope and peace. When science meets patient time, even a stock can get new life. So now Photocure rebounds on the stock exchange, expectation becomes power, and power gets a course. If the approval comes – who knows when, but the market sings: we believe in this year. Yes, now Photocure rebounds on the stock exchange, and the future feels a little less dark.
- ·1 päivä sittenFrom user Aribijo on TI: From China forum: “The 1702 comprehensive review ended on December 26. The general administrative approval process takes 3-5 working days. The last step of drug approval is the administrative process, but it involves cross-departmental handover, and occasionally there will be a few days of delay. These two weeks after New Year’s Day are very critical time windows. There is a possibility of a drug registration approval at any time.”
- ·1 päivä sittenI have asked ChatGPT about the current status of approval with China's National Medical Products Administration (NMPA). Here is the answer: From Asieris' half-year report (August 2025): Asieris' CEO Dr. Kevin Pan stated: "A remarkable achievement is the steady progress in the regulatory review for APL-1702, our breakthrough therapy for precancerous lesions of the cervix, which is now entering the final stages before launch in China and is ready to benefit patients soon" The report further states that APL-1702 is "in the final stages before the China launch" and that "the regulatory review is progressing smoothly, with NMPA having initiated a second round of technical evaluation" Key signals Positive tone: The phrasing "steady progress" and "final stages" is a good sign. If there were major problems, such positive phrasing would hardly be used. Approval probability: APL-1702 is described as "ready to become the world's first non-invasive therapy for HSIL, supported by robust clinical evidence and validated in an international Phase III study" USA plans: Asieris has also entered into an agreement with FDA on the design of a new Phase III study to support potential USA approval of APL-1702, and the company is seeking foreign partners to prepare USA IND submission Based on this information from August 2025, it looks promising. The wording suggests that they expect approval relatively soon, and that there are no significant problems in the process. The fact that they are also planning for the USA market indicates confidence in the product.
- ·1 päivä sittenTick tock tick tock. A decision on Cevira coming to market could be very close.·1 päivä sittenExtremely exciting days in PHO currently, the approval can literally come any day.
- ·2 päivää sittenIt didn't last long...... 💩💩·1 päivä sitten5,5 mill. has been traded. That is quite a lot. The normal has been somewhere between 1,5-2. so this is a good sign.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
436
Myynti
Määrä
388
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 60 | - | - | ||
| 20 | - | - | ||
| 600 | - | - | ||
| 533 | - | - |
Ylin
74,8VWAP
Alin
73,1VaihtoMäärä
2,8 37 832
VWAP
Ylin
74,8Alin
73,1VaihtoMäärä
2,8 37 832
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 19.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
70 päivää sitten46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 29.10.2025 | |
| 2025 Q2 -tulosraportti | 30.7.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 19.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 t sittenIt was quiet on the screen, the numbers were flat, red arrows whispered of a heavy night. But beneath the surface, in another land, a hope lay waiting – a yes from China's hand. Analyst's gaze and coffee cup, rumors spread before the sun comes up. Something is on its way, something is near, Cevira is knocking on a door there. And now Photocure rebounds on the stock exchange, like a wave finally finding its course. Expectations lift every single krone, China watches – and the market awakens to a tune. Yes, now Photocure rebounds on the stock exchange, faith meets numbers, and hope gets a pulse. Years of work, studies and faith, in lab and meetings, step by step in peace. A market so large, a light so clear, an approval can change everything, soon. The graphs tremble, the volume laughs, some buy early, others watch. It's not just about profit, but about future, patients, and a new beginning at last. And now Photocure rebounds on the stock exchange, after headwinds finally comes a course. Cevira in sight, China in play, the market answers: we believe, we will. Yes, now Photocure rebounds on the stock exchange, a small company with a global pulse. It's not just numbers going up and down, but stories of breakthroughs, hope and peace. When science meets patient time, even a stock can get new life. So now Photocure rebounds on the stock exchange, expectation becomes power, and power gets a course. If the approval comes – who knows when, but the market sings: we believe in this year. Yes, now Photocure rebounds on the stock exchange, and the future feels a little less dark.
- ·1 päivä sittenFrom user Aribijo on TI: From China forum: “The 1702 comprehensive review ended on December 26. The general administrative approval process takes 3-5 working days. The last step of drug approval is the administrative process, but it involves cross-departmental handover, and occasionally there will be a few days of delay. These two weeks after New Year’s Day are very critical time windows. There is a possibility of a drug registration approval at any time.”
- ·1 päivä sittenI have asked ChatGPT about the current status of approval with China's National Medical Products Administration (NMPA). Here is the answer: From Asieris' half-year report (August 2025): Asieris' CEO Dr. Kevin Pan stated: "A remarkable achievement is the steady progress in the regulatory review for APL-1702, our breakthrough therapy for precancerous lesions of the cervix, which is now entering the final stages before launch in China and is ready to benefit patients soon" The report further states that APL-1702 is "in the final stages before the China launch" and that "the regulatory review is progressing smoothly, with NMPA having initiated a second round of technical evaluation" Key signals Positive tone: The phrasing "steady progress" and "final stages" is a good sign. If there were major problems, such positive phrasing would hardly be used. Approval probability: APL-1702 is described as "ready to become the world's first non-invasive therapy for HSIL, supported by robust clinical evidence and validated in an international Phase III study" USA plans: Asieris has also entered into an agreement with FDA on the design of a new Phase III study to support potential USA approval of APL-1702, and the company is seeking foreign partners to prepare USA IND submission Based on this information from August 2025, it looks promising. The wording suggests that they expect approval relatively soon, and that there are no significant problems in the process. The fact that they are also planning for the USA market indicates confidence in the product.
- ·1 päivä sittenTick tock tick tock. A decision on Cevira coming to market could be very close.·1 päivä sittenExtremely exciting days in PHO currently, the approval can literally come any day.
- ·2 päivää sittenIt didn't last long...... 💩💩·1 päivä sitten5,5 mill. has been traded. That is quite a lot. The normal has been somewhere between 1,5-2. so this is a good sign.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
436
Myynti
Määrä
388
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 60 | - | - | ||
| 20 | - | - | ||
| 600 | - | - | ||
| 533 | - | - |
Ylin
74,8VWAP
Alin
73,1VaihtoMäärä
2,8 37 832
VWAP
Ylin
74,8Alin
73,1VaihtoMäärä
2,8 37 832
Välittäjätilasto
Dataa ei löytynyt